The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Open accessAbstract
BACKGROUND: Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 diabetes. METHODS: In this 6-month randomized, multicenter trial, patients with type 1 diabetes were assigned in a 2:1 ratio to receive treatment with a closed-loop system (closed-loop group) or a sensor-augmented pump (control group). The primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter), as measured by continuous glucose monitoring. RESULTS: A total of 168 patients underwent randomization; 112 were assigned to the closed-loop group, and 56 were assigned to the control group. The age range of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%. All 168 patients completed the trial. The mean (±SD) percentage of time that the glucose level was within the target range increased in the closed-loop group from 61±17% at baseline to 71±12% during the 6 months and remained unchanged at 59±14% in the control group (mean adjusted difference, 11 percentage points; 95% confidence interval [CI], 9 to 14; P<0.001). The results with regard to the main secondary outcomes (percentage of time that the glucose level was >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that the glucose level was <70 mg per deciliter or <54 mg per deciliter [3.0 mmol per liter]) all met the prespecified hierarchical criterion for significance, favoring the closed-loop system. The mean difference (closed loop minus control) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter was -0.88 percentage points (95% CI, -1.19 to -0.57; P<0.001). The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 percentage points (95% CI, -0.53 to -0.13; P = 0.001). In the closed-loop group, the median percentage of time that the system was in closed-loop mode was 90% over 6 months. No serious hypoglycemic events occurred in either group; one episode of diabetic ketoacidosis occurred in the closed-loop group. CONCLUSIONS: In this 6-month trial involving patients with type 1 diabetes, the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; iDCL ClinicalTrials.gov number, NCT03563313.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The largest trial with this class in T1D was with liraglutide, which showed a reduction of A1C of 0.4% with the highest 1.8 mg dose in addition to a 5 kg weight loss and insulin dose reductions.1177”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, the introduction of CGM devices that alarm with low blood glucose concentrations and semiautomated pumps that suspend insulin infusion as glucose concentrations decrease have facilitated achieving target HbA 1c levels with less risk for hypoglycemia (332).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [332]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hybrid closedloop systems are the most effective means of maintaining glucose in the normal range in people with type 1 diabetes (90,91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of insulin analog regimens are associated with less hypoglycemia, while hybrid closed-loop systems result in both improvement in TIR and reduction in TBR (91).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [91]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These prestigious publications reported pivotal trials of the commercial descendant of DiAs-a new AID system (Control-IQ by Tandem Diabetes Care)-in different age groups: 14 years old and older, 132 6 to 13 years old, 133 and 2 to 6 years old.134”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“This large-scale study and its continuation with young children ages 2 to 6 years old completed several clinical protocols, three of which were published in the New England Journal of Medicine.[132][133][134]”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“In particular, glucose time in range (70 -180 mg/dl [3.9 -10.0 mmol/l]) and time in hypoglycemia ( < 70 mg/dl [3.9 mmol/l] and < 54 mg/dl [3.0 mmol/l]) have been used as outcomes for clinical trials 259,260 and have been endorsed as appropriate metrics for clinical care. 229”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [260]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that an AID hybrid closed-loop system is superior to AID sensor-augmented pump therapy for increased percentage of time in range and reduction of hypoglycemia (34,35).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [34]
The cited source says what the claim attributes to it.
In the citing paper
“HbA 1c , TIR, and TBR are improved further when physiological MDI or pump regimens are augmented with CGM usage (89), with the greatest benefits seen with algorithm-driven automated basal (and in some systems correction) insulin delivery, which is commonly called hybrid closed-loop therapy (90,91).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although this agent was more effective with those participants still producing endogenous insulin, the added hypoglycemia and ketosis noted has resulted in no attempt for FDA approval in T1D.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1177]
Experimental — accuracy not yet measuredIn the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [208]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644
Self-citationWeisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463
Tauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Kleinman, L. C., & Norton, E. C. (2008) · Health Services Research · doi:10.1111/j.1475-6773.2008.00900.x · Cited by 287
Forlenza, G. P., Li, Z., Buckingham, B. A., Pinsker, J. E., Cengiz, E., Wadwa, R. P., Ekhlaspour, L., Church, M. M., Weinzimer, S. A., Jost, E., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0771 · Cited by 246
Self-citationBenhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 999
Dynamic Insulin Basal Needs Estimation and Parameters Adjustment in Type 1 Diabetes
Berián, J., Bravo, I., Gardel, A., Galilea, J. L. L., & Rigla, M. (2021) · Sensors · doi:10.3390/s21155226 · Cited by 6
Clinical Evaluation of a Novel Insulin Immunosensor
Aiello, E. M., Pinsker, J. E., Vargas, E., Teymourian, H., Tehrani, F., Church, M. M., Laffel, L. M., Doyle, F. J., Patti, M., Wang, J., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221074406 · Cited by 6
Self-citationBenhamou, P., Adenis, A., Lablanche, S., Franc, S., Amadou, C., Penfornis, A., Kariyawasam, D., Beltrand, J., & Charpentier, G. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231186976 · Cited by 6
Nonadjunctive Use of Continuous Glucose Monitoring: The End of Fingersticks?
Beck, R. W., Brown, S. A., Lum, J. W., & Kovatchev, B. P. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0387 · Cited by 6
Self-citationLiu, J. J., Spakowicz, D. J., Ash, G. I., Hoyd, R., Zhang, A., Lou, S., Lee, D., Zhang, J., Presley, C., Greene, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.02.973677 · Cited by 6
Lei, M., Ling, P., Lin, B., Lv, J., Liu, Z., Zhou, Y., Deng, H., Yang, D., Wang, C., Yang, X., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16505 · Cited by 5
Metabolic Models, in Silico Trials, and Algorithms
Çınar, A., Basu, A., Bequette, B. W., Breton, M. D., Buckingham, B. A., Cengiz, E., Cobelli, C., Dassau, E., Doyle, F. J., Fabris, C., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.18800.ac · Cited by 5
Self-citationBuilding immune digital twins: An international and transdisciplinary community effort
Niarakis, A., An, G. C., Ladeira, L., Hiroi, N. F., Papadopoulou, A., Crawley, F. P., Nikaein, N., Calzone, L., Tsirvouli, E., Balcı, H., et al. (2025) · ImmunoInformatics · doi:10.1016/j.immuno.2025.100060 · Cited by 5
Digital management of diabetes global research trends: a bibliometric study
Zhu, S., Bian, H., Zhan, J., Ni, L., Huo, L., & Hu, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1620307 · Cited by 7
Systematic Review on Deep Learning Algorithms for Blood Glucose Forecasting in Type 1 Diabetes
Calzavara, A., Prendin, F., Cappon, G., Favero, S. D., & Facchinetti, A. (2026) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2025.3630214 · Cited by 10
Rethinking control‐ IQ + technology: Simple strategies for easy optimization
Shah, V. N., Choudhary, P., Halperin, I. J., Rabbone, I., Zaharieva, D. P., & Messer, L. H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70500 · Cited by 5
Chowdhury, S., Sarkar, S., Das, A., Kar, K., & Chakraborty, P. (2026) · Next Bioengineering · doi:10.1016/j.nxbio.2026.100027 · Cited by 5
McKee, A. M., Al-Hammadi, N. J., & Hinyard, L. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.05.001 · Cited by 5
Takai, T., Okada, Y., Takebe, R., & Nakamura, T. (2021) · Diabetology International · doi:10.1007/s13340-021-00539-w · Cited by 4
Lin, Y. K., Aikens, J. E., de Zoysa, N., Hall, D., Funnell, M. M., Nwankwo, R. B., Kloss, K., DeJonckheere, M. J., Pop‐Busui, R., Piatt, G., et al. (2023) · JMIR Formative Research · doi:10.2196/50374 · Cited by 5
Real-life data of hypoglycemic events in children and adolescents with type 1 diabetes
Hill, H., Klaar, P., & Espes, D. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003485 · Cited by 5
Roberts, A., Dart, J., Lloyd, S., Bebbington, K. R., Fairchild, J. M., Ambler, G. R., Cameron, F. J., Davis, E. A., Jones, T. W., & Abraham, M. B. (2024) · Pediatric Diabetes · doi:10.1155/2024/6260002 · Cited by 5
Emerging role of gene therapy in immune modulation and beta-cell preservation in Type 1 diabetes
Mittal, R., Mutha, V., Valerio, E. A., Hirani, K., Arevalo, G., Panchal, A., Mittal, M., Lemos, J. R. N., & Hirani, K. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2522869 · Cited by 5
Pham, A. Q., Lingvay, I., Ahmadi, N., Santiago-Munoz, P. C., & Abreu, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112454 · Cited by 5
To sleep or not to sleep: An Italian Control-IQ-uestion
Bassi, M., Strati, M. F., Andreottola, V., Calevo, M. G., d’Annunzio, G., Maghnie, M., & Minuto, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.996453 · Cited by 5
Mizokami‐Stout, K., Thompson, H. M., Hurren, K. M., LEONE, V. A., Piatt, G., Lee, J. M., Pop‐Busui, R., & DeJonckheere, M. J. (2023) · JMIR Diabetes · doi:10.2196/45241 · Cited by 5
Banca, R. O. L., Volkening, L. K., Mehta, S. N., Dassau, E., & Laffel, L. M. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0464 · Cited by 5
Self-citationHypoglycemia in Type 1 Diabetes Mellitus
Şakar, K., & Çınar, N. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004108 · Cited by 6
Suboptimally Controlled Diabetes in Pregnancy: A Review to Guide Antepartum and Delivery Management
Cate, J. J. M., Bloom, E. A., Chu, A., Bauer, S., Kuller, J. A., & Dotters-Katz, S. K. (2024) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001270 · Cited by 6
Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020
Rhee, E., Kim, M. K., & Lee, W. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.106 · Cited by 6
Individualisierung der Diabetestherapie durch Automatisierung der Insulingabe
Biester, T., Dovč, K., Chobot, A. P., Tauschmann, M., & Kapellen, T. M. (2021) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-021-01239-0 · Cited by 4
Santos, T. J. D., Rodrigues, T. D. C., Puñales, M. K., Arrais, R. F., & Kopacek, C. (2021) · Current Pediatrics Reports · doi:10.1007/s40124-021-00248-7 · Cited by 6
Lin, Y. K., Richardson, C. R., Dobrin, I., Pop‐Busui, R., Piatt, G., & Piette, J. D. (2022) · JMIR Diabetes · doi:10.2196/36140 · Cited by 7
Decision Support Systems and Closed Loop
Nimri, R., Piper, M. M., Pinsker, J. E., & Dassau, E. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.2504 · Cited by 5
Self-citationDeichmann, J., & Kaltenbach, H. (2023) · Journal of Process Control · doi:10.1016/j.jprocont.2023.103042 · Cited by 5
Closed loop insulin delivery–Opportunities and limitations
Weiss, R. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13490 · Cited by 4
Closed-loop insulin delivery: understanding when and how it is effective
Benhamou, P., & Reznik, Y. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30219-5 · Cited by 5
Omnipod 5 in children and adolescents with type 1 diabetes: Improved outcomes with fewer boluses
Tinti, D., Castorani, V., Nobili, C., Felappi, B., Prandi, E., Piccini, B., Toni, S., Bassi, M., Minuto, N., Bonfanti, R., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16436 · Cited by 4
Recent Advances in Electrically Stimulated Insulin Delivery Systems
Alemán, C., Muñoz-Galán, H., & Pérez‐Madrigal, M. M. (2025) · ACS Omega · doi:10.1021/acsomega.5c06147 · Cited by 5
Fabris, C., Flanagan, D., Bennett, C., Batista, A. F. M. B., Oliveri, M. C., & Gonder-Frederick, L. A. (2025) · Diabetes Spectrum · doi:10.2337/ds25-0003 · Cited by 4
Elmotia, K., Abouyaala, O., Bougrine, S., & Ouahidi, M. L. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.05.004 · Cited by 5
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems
Jacobs, P. G., Levy, C. J., Brown, S. A., Riddell, M. C., Çınar, A., Boughton, C. K., Breton, M. D., Dassau, E., Forlenza, G. P., Henderson, R. J., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0129 · Cited by 5
Self-citationInsulin Pumps for Individuals With Type 2 Diabetes
Brown, S. M., Romeo, G. R., & Toschi, E. (2025) · Diabetes Spectrum · doi:10.2337/dsi25-0005 · Cited by 5
Self-citationBlervaque, J., Vesin, A., Benhamou, P., & Lablanche, S. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251362700 · Cited by 4
Evolution of the Artificial Pancreas: Components and Integration—CGMs, Insulin, and AP Systems
Bergenstal, R. M., Heller, A., Breton, M. D., Vigersky, R. A., Brown, S. A., Forlenza, G. P., Sherr, J. L., Hovorka, R., Russell, S. J., Damiano, E. R., et al. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.18801.rmb · Cited by 5
Self-citationKudva, Y. C., & Nair, K. S. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.11.016 · Cited by 4
Self-citationReal-World Glycemic Improvements with Hybrid Closed Loop Pumps in Youth with Type 1 Diabetes
Rolón, M. E. D. V., Brown, E. A., & Wolf, R. M. (2023) · Pediatric Diabetes · doi:10.1155/2023/6621706 · Cited by 5
Wu, Z., Talbo, M. K., Lebbar, M., Messier, V., Courchesne, A., Brazeau, A., & RABASA-LHORET, R. P. R. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111006 · Cited by 4
Kişiselleştirilmiş Tıp İçin Dijital İkiz: Sistematik Derleme
Dilek, A. L. A. Y. (2024) · Sağlık Profesyonelleri Araştırma Dergisi · doi:10.57224/jhpr.1342561 · Cited by 5
Scheinker, D., & Maahs, D. M. (2024) · Diabetes Care · doi:10.2337/dc24-1682 · Cited by 4
Accounting for Hypoglycemia Treatments in Continuous Glucose Metrics
Pryor, E. C., Fathi, A. E., & Breton, M. D. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251329952 · Cited by 4
Gad, H., Elgassim, E., Mohamud, K., Al‐Naimi, N. S., Al-Sharshani, H., Mohammed, I., Al-Malaheem, M. A. O., Quadros, D. J., AlJalahma, A., Lamine, N., et al. (2025) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70026 · Cited by 4
Metabolic Models, in Silico Trials, and Algorithms
Çınar, A., Basu, A., Bequette, B. W., Breton, M. D., Buckingham, B. A., Cengiz, E., Cobelli, C., Dassau, E., Doyle, F. J., Fabris, C., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251338300 · Cited by 5
Self-citationTechnologies in the management of type 1 diabetes
SNAITH, J. R., & Holmes-Walker, D. J. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.50946 · Cited by 4
Hundert Jahre – Insulin bleibt aktuell und notwendig
Landgraf, R., & Aberle, J. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1386-0011 · Cited by 4
Empfehlungen zur Diabetes-Behandlung mit automatischen Insulin-Dosierungssystemen
Berge, T. V. D., Biester, S., Biester, T., Buchmann, A.-K., Datz, N., Grosser, U., Kapitzke, K., Klusmeier, B., Remus, K., Reschke, F., et al. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1652-9011 · Cited by 4
Sathyanarayanan, A., Crabtree, T. S. J., Choudhary, P., Elliott, D., Evans, M. L., Lumb, A. N., & Wilmot, E. G. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109777 · Cited by 4
Campanella, S., Sabbatini, L., Cherubini, V., Tiberi, V., Marino, M., Pierleoni, P., Belli, A., Boccolini, G., & Palma, L. (2022) · Electronics · doi:10.3390/electronics11142227 · Cited by 4
Courtney, A., Smith, D., & Forde, H. E. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03322-9 · Cited by 4
Kubota, S., Sato, A., Hosokawa, M., Okubo, Y., Takayama, S., Kaneko, A., Shimada, Y., Asano, Y., Sato, Y., Yamazaki, M., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej24-0136 · Cited by 4
Sehgal, S., de Bock, M. I., Grosman, B., Williman, J. A., Kurtz, N., Guzman, V., Benedetti, A., Roy, A., Turksoy, K., Juarez, M., et al. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01709-y · Cited by 4
Customized treatment for Type 1 diabetes patients using novel software
Zeller, W. P., DeGraff, B. R., & Zeller, W. (2020) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2020.100057 · Cited by 4
Jacobasch, G., Bleiber, R., & Schönian, G. (1982) · PubMed · Cited by 4
Use of Patient-Reported Outcomes for Assessing Diabetes Outcomes
Kim, H., Shah, K. P., & Buettner, C. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.05.001 · Cited by 4
Renard, É. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820901612 · Cited by 4
More Focus is Needed to Reduce Adverse Events for Diabetes Devices
Krouwer, J. S. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820951625 · Cited by 4
Towards a Rational Balanced Pancreatic and Islet Allocation Schema
KANDEEL, F. R., El-Shahawy, M. A., Singh, G. P., Dafoe, D. C., Isenberg, J. S., & Riggs, A. D. (2021) · Cell Transplantation · doi:10.1177/09636897211057130 · Cited by 4
Guideline Development for Medical Device Technology: Issues for Consideration
Battelino, T., Brosius, F. C., Ceriello, A., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., Lalic, N. M., Marx, N., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221093355 · Cited by 4
Closed-Loop, Artificial Intelligence-Based Decision Support Systems, and Data Science
Nimri, R., Phillip, M., Clements, M. A., & Kovatchev, B. P. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8805.rev · Cited by 5
Self-citationMeade, L. T., Marino, A. B., Barrier, M. A., & Wilson, M. H. (2024) · Diabetes Spectrum · doi:10.2337/ds23-0057 · Cited by 3
Gehrmann, F. E., Smith, G. J., Irwine, K., Ellis, K. L., Davis, E. A., Jones, T. W., Taplin, C. E., & Abraham, M. B. (2024) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.16723 · Cited by 3
Tatulashvili, S., Dreves, B., Cosson, E., Meyer, L., Morello, R., & Joubert, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318746 · Cited by 3
Ware, J., Bergford, S., Calhoun, P. M., Sibayan, J., Wilinska, M. E., Ruan, Y., & Hovorka, R. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251376010 · Cited by 3
Do, Q. D., Radovnická, L., Hašková, A., Konečná, J., Horová, E., Grunberger, G., Prázný, M., Parkin, C. G., Flekač, M., & Šoupal, J. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251376013 · Cited by 3
Guo, Q., Xu, W., Wang, C., Xie, M., Wu, Z., Zhang, N., Zhang, B., & Mu, D. (2025) · Nutrition Journal · doi:10.1186/s12937-025-01205-6 · Cited by 3
Oktavian, P., Wungu, C. D. K., Wibisono, S., & Amin, I. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.198 · Cited by 3
Diabetes mellitus and work participation
Tomic, D., Walker-Bone, K. E., Keegel, T. G., Zomer, E., Zoungas, S., & Magliano, D. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01194-w · Cited by 3
Karim, A. M. (2025) · Bioengineering · doi:10.3390/bioengineering12121309 · Cited by 3
Ståhl, F. L., Hellman, J., & Ekelund, C. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251414976 · Cited by 4
Ward, M. C., Boucsein, A., Zhou, Y., Michaels, V. R., Haszard, J. J., Jefferies, C., Wiltshire, E. J., Paul, R. G., Lopez-Sanchez, C. A., de Bock, M. I., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261426883 · Cited by 3
Kok, N., Williamson, W. T., Lee, J. M., & Gaynanova, I. (2026) · Diabetes Care · doi:10.2337/dc25-2935 · Cited by 3
Jacobsen, S. S., Hommel, E. E., Ranjan, A. G., & Nørgaard, K. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0532 · Cited by 3
Evaluation of a New Clinical Tool to Enhance Clinical Care of Control-IQ Users
Messer, L. H., Berget, C., Centi, S. M., McNair, B. K., & Forlenza, G. P. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221081890 · Cited by 3
Self-citationAleppo, G., Bode, B. W., & Carlson, A. L. (2022) · Clinical Diabetes · doi:10.2337/cd21-0056 · Cited by 3
Evaluation of a High Sensitivity Glucose Biosensor Based on Carbon Nanotubes and Gold Nanoparticles
Liu, L., Li, Y., Liang, J., Zhang, L., & Zhang, J. (2024) · IEEE Sensors Journal · doi:10.1109/jsen.2024.3466244 · Cited by 3
Nattero‐Chávez, L., de la Villa, E. D. L. C., Pascual, E. L., Cebada, A. B., Gracia, T. R., Tobar, A. Q., Moñino, M. L., Rodríguez, C. S., Izquierdo, A., Escobar-Morreale, H. F., et al. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241288789 · Cited by 3
Overview of Currently Available Insulin Delivery Systems
Fried, H. (2024) · Contemporary Endocrinology · doi:10.1007/978-3-031-75352-7_2 · Cited by 3
ARPA-H for Radiologists: Novel Funding Opportunities and Results of a National Survey
Lee, Y. Z., Ikuta, I., Jawahar, A., Wilkinson, J., Cappelletti, C., Cruea, R. L., & Ho, M. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.11.001 · Cited by 3
Novodvorský, P., Bernjak, A., Downs, E., Smith, A., Arshad, M. F., Oprescu, A. I., Jacques, R., Lee, J., Heller, S. R., & Iqbal, A. (2025) · Diabetic Medicine · doi:10.1111/dme.70019 · Cited by 3
Shen, J., Castillo, A., & Pryor, E. C. (2025) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2025.06.012 · Cited by 3
Choe, J., Belmonte, P. J., Crotts, S. B., Nguyen, T., Friedman, D. J., Zastrow, A. L., Rajcula, M. J., Hammer, B., Wilhelm, C., Shapiro, M. J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181207 · Cited by 3
A Modified CGM Algorithm Enhances Data Availability While Retaining iCGM Performance
Towers, R. A. H., Zhang, X., Yousefi, R., Esmaili, G. R., Wang, L., Garcia, A., & Beck, S. E. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211007521 · Cited by 3
Management of Type 1 Diabetes in Children in the Outpatient Setting
Jackson, S. C., Creo, A. L., & Nofal, A. A. (2022) · Pediatrics in Review · doi:10.1542/pir.2020-001388 · Cited by 3
Simmons, K., & Riddley, S. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.005 · Cited by 15
Peters, C. J., Annan, F., Hindmarsh, P. C., & Thompson, R. J. (2021) · Paediatrics and Child Health · doi:10.1016/j.paed.2021.01.002 · Cited by 3
Hybrid Closed-Loop Insulin Delivery Systems for People With Type 1 Diabetes
Service, C. H. T. A. (2021) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2021.50 · Cited by 3
Variation of glucose time in range in type 1 diabetes
Hansen, K. W., & Bibby, B. M. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.379 · Cited by 2
RAIMOND, L. H., O’Donnell, S., Bøggild-Damkvist, T., Filges, T., & Lomborg, K. E. (2022) · Chronic Illness · doi:10.1177/17423953221142341 · Cited by 3
Ware, J., Wilinska, M. E., Ruan, Y., Allen, J. M., Boughton, C. K., Hartnell, S., Bally, L., de Beaufort, C. E., Besser, R. E. J., Campbell, F., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221141924 · Cited by 3
Grundman, J., Majidi, S., PERKINS, A. G., Streisand, R. M., Monaghan, M. C., & Marks, B. E. (2023) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2023.101067 · Cited by 3
Dover, A. R., Ritchie, S. A., Wright, R. J., McMurray, E. M., Strachan, M. W. J., Stimson, R. H., Forbes, S., & Gibb, F. W. (2023) · Diabetic Medicine · doi:10.1111/dme.15058 · Cited by 3
Closing the loop on adrenal health, dysfunction, and disease
Mohan, D. R., & Lerário, A. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4450 · Cited by 4
Navas-Moreno, V., Sebastián‐Valles, F., Sampedro-Nuñez, M. A., Vargas, M. L., Marazuela, M., & Martín, J. A. A. (2023) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2023.06.005 · Cited by 3
Lim, R. J., Abraham, M., Nicholls, R., Fournier, P. A., & Harray, A. (2023) · Journal of Pediatric Endocrinology and Diabetes · doi:10.25259/jped_18_2023 · Cited by 2
Impact of pancreas transplantation alone on kidney function: A multicenter clinical cohort study
Kaur, R. J., Mujtahedi, S., Fridell, J. A., Benavides, X., Smith, B. H., Larson, T. S., Rizvi, S., Kukla, A., Dean, P. G., Kudva, Y. C., et al. (2023) · Clinical Transplantation · doi:10.1111/ctr.15212 · Cited by 3
Self-citation
Metadata
- Authors
- Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., Dassau, E., Doyle, F. J., Anderson, S. M., Church, M. M., Dadlani, V., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Kollman, C., & Beck, R. W.
- Affiliations
- Sansum Diabetes Research Institute (US)
- Mayo Clinic (US)
- Joslin Diabetes Center (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-31
- Volume
- 381
- Issue
- 18
- Pages
- 1707-1717
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7076915
- OpenAlex
- W2981310284
- Semantic Scholar
- a8aee7f3c717498afd65ea39bd87dd1c1ea5d693
- Cited by
- 1,030
- References
- 17
- Citations by year
- 2026: 128 · 2025: 134 · 2024: 140 · 2023: 180 · 2022: 158 · 2021: 156 · 2020: 125 · 2019: 8
- FWCI
- 90.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- HAL (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4 DK108483)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, artificial pancreas, sensor-augmented pump, continuous glucose monitoring, glycemic control, HbA1c, hypoglycemia, hyperglycemia, insulin pump therapy, glycemic variability, HbA1c reduction, hypoglycemia risk reduction, HbA1c thresholds, hypoglycemia risk
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Equipment Design, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, Pancreas, Artificial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
